Skip to main content
ACXP
NASDAQ Life Sciences

Acurx Enrolls First Patient in PATHFINDER Trial for Recurrent C. difficile

Tom Rudovsky · Reported by PR Newswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.412
Mkt Cap
$7.45M
52W Low
$1.305
52W High
$8.34
52W Position info
8.2% above low
Off High info
83% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

ACXP is trading near its 52-week low of $1.305 (8.2% above the low).

Summary

Acurx has enrolled the first patient in its PATHFINDER Phase 2 trial of ibezapolstat for multiply-recurrent C. difficile infection. The trial is fully funded and will enroll approximately 20 patients, with data intended to support an NDA filing based on a single Phase 3 trial. This follows FDA meeting minutes from August indicating a potential streamlined approval path. The company remains subject to a going concern warning, but this milestone advances its lead asset toward registration.

At the time of this announcement, ACXP was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $1.31 to $8.34. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

ACXP - Latest Insights

ACXP
Nov 12, 2026, 6:46 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.966
Real-time Price: $1.01 info
Change: +$0.0439 (+5%) info
Market Cap: $6.118M info
ACXP
Aug 17, 2026, 8:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $1.01 info
Change: -$0.3501 (-26%) info
Market Cap: $6.118M info
ACXP
Aug 14, 2026, 7:01 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.01 info
Change: -$0.6201 (-38%) info
Market Cap: $6.118M info
ACXP
Aug 13, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.55
Real-time Price: $1.01 info
Change: -$0.5376 (-35%) info
Market Cap: $6.118M info
ACXP
Aug 03, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $1.45
Real-time Price: $1.01 info
Change: -$0.4401 (-30%) info
Market Cap: $6.118M info